1998 December Genetic instabilities in human cancers. Whether and how human tumours are genetically unstable has been debated for decades. READ 2001 July Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Bisulfite genomic sequencing is the method of choice for the generation of methylation maps with single-base resolution. READ 2005 January An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. Recent studies have shown that DNA methylation (DNAm) markers in peripheral blood may hold promise as diagnostic or early detection/risk markers for epithelial cancers. READ 2005 January Leukocyte DNA Methylation Signature Differentiates Pancreatic Cancer Patients from Healthy Controls. Pancreatic adenocarcinoma (PaC) is one of most difficult tumors to treat. READ 2005 January Prediction of cancer outcome with microarrays: A multiple random validation strategy. General studies of microarray gene-expression profiling have been undertaken to predict cancer outcome. READ 2006 May Aging, inflammation and cancer. In the intrinsic pathway, genetic events that cause neoplasia (oncogenes and oncosupressor genes) orchestrate the construction of cancer-related inflammation. READ 2010 January Impact of cytosine methylation on DNA binding specificities of human transcription factors. Nearly all cells in the human body share the same primary genome sequence consisting of four nucleotide bases. READ 2010 January Epigenetics in cancer. Epigenetic mechanisms are essential for normal development and maintenance of tissue-specific gene expression patterns in mammals. READ 2011 December Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004. Cancer, the major killer disease of the century requires a multi-pronged approach and among the latest modalities of treatments, Immunotherapy occupies a promising role. READ 2011 December Targeting cytotoxic T lymphocytes for cancer immunotherapy. In light of their preeminent role in cellular immunity, there is considerable interest in targeting of cytotoxic T-lymphocytes to cancer. READ 2011 December Cancer immunotherapy comes of age. Activating the immune system for therapeutic benefit in cancer has long been a dream of some immunologists, and even a few oncologists. READ 2011 December Adoptive T cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology. Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows promise in recent trials. READ 2011 December Adoptive-Cell-Transfer therapy for the treatment of patients with cancer. Adoptive immunotherapy — the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration — is a promising approach to inducing antitumour immune responses. READ 2011 December Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: A Comprehensive Review from Tumor Microenvironment to Gut Microbiota. Over the years, researchers tried to explain cancer pathogenesis by taking into consideration different factors, such as immune system, the genetic predisposition and environmental factors. READ 2012 March Methylome analysis using MeDIP-seq with low DNA concentrations. DNA methylation is an epigenetic mark that has a crucial role in many biological processes. READ 2013 December Reference range and short- and long-term biological variation of interleukin (IL)-6, IL-17A and tissue necrosis factor-alpha using high sensitivity assays. nterleukin (IL)-6, and tissue necrosis factor alpha (TNF-α) are established biomarkers for clinical practice and use in clinical trials of patients with cardiovascular disease. READ 2014 February Liquid biopsies: genotyping circulating tumor DNA. Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. READ 2014 November An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Circulating tumor DNA (ctDNA) represents a promising biomarker for noninvasive assessment of cancer burden, but existing methods have insufficient sensitivity or patient coverage for broad clinical applicability. READ 2014 November Detection and localization of surgically resectable cancers with a multi-analyteblood test. Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. READ 2015 March Mesenchymal stem cells as delivery vectors for anti-tumor therapy. Recent studies have demonstrated mesenchymal stem cells (MSCs) are able to migrate specifically to tumors and their metastatic sites when administered intravenously. READ 2015 September Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Plasma consists of DNA released from multiple tissues within the body. READ 2015 September Somatic mutation in cancer and normal cells. Spontaneously occurring mutations accumulate in somatic cells throughout a person’s lifetime. READ 2016 March Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. Epigenetic alterations measured in blood may help guide breast cancer treatment. READ 2016 March Noninvasive detection of cancer- associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Genome-wide hypomethylation is frequently observed in cancers. READ 2016 March Identification of tissue-specific cell death using methylation patterns of circulating DNA. We describe a blood test for detection of cell death in specific tissues based on two principles: (i) dying cells release fragmented DNA to the circulation, and (ii) each cell type has a unique DNA methylation pattern. READ 2016 March Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. Targeted cancer therapeutics are promised to have a major impact on cancer treatment and survival. READ 2016 March Oncomine cfDNA assays. The Oncomine cfDNA assays have been developed together with the OncoNetwork Consortia. READ 2016 May From inflammation to cancer. The participation of inflammation in the progression of cancer for many years have been the subject of research. READ 2016 June Extraction and analysis of circulating cell-free DNA from plasma samples for lung cancer research. Development of drugs targeting driver genes involved in lung cancer progression has become essential for the advancement of treatment options. READ 2016 June A research approach for the detection of somatic mutations at 0.5% frequency from cfDNA and cTcDNA using a multiplex sequencing assaytargeting 2800 tumor mutations. Availability of effective blood analysis process for tracking of recurrence and resistance of tumors may improve outcomes in the future. READ 2016 June A Multi-Center Assessment of a Next-Generation Sequencing Assay for Detection of Germline and Somatic BRCA1 and BRCA2 Gene Variants from Formalin-Fixed, Paraffin-Embedded Samples. We designed a new, highly multiplexed amplification-based assay which allows detection of BRCA1 and BRCA2 gene variants in somatic and germline samples through semiconductor-based DNA sequencing. READ 2016 August RANK–RANKL signalling in cancer Oncogenic events combined with a favourable environment are the two main factors in the oncological process. READ 2016 August Direct detection of early-stage cancers using circulating tumor DNA. Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. READ 2016 August Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin To identify a multitissue, molecular signature-based classifi- cation of cancer objectively, we first characterized each of the individual tumor types using six different ‘‘omic’’ platforms. READ 2016 September Circulating tumor DNA detection in lung cancer patients before and after surgery. Circulating tumor DNA (ctDNA) in peripheral blood is a “liquid biopsy” that contains representative tumor information including gene mutations. READ 2016 August AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. READ 2016 September Integrated digital error suppression for improved detection of circulating tumor DNA. High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate personalized cancer therapy. READ 2016 October Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. The advent of genomic based personalized medicine has led to multiple advances in the molecular characterization of many tumor types, such as non-small cell lung cancer (NSCLC). READ 2016 October Next-generation sequencing analysis of low-frequency mutations from cell-free DNA. Advanced molecular profiling methods using NGS are enabling clinical researchers to accurately profile mutations of interest in blood samples. READ 2017 January Clinical Next-Generation Sequencing for Somatic Mutation Detection-Advancements and Commercialization Strategies. dvancements in next-generation sequencing, variant-calling software, and mutation enrichment are facilitating the detection of rare genetic variants. READ 2017 February Analytical verification methods for the Oncomine Lung cfDNA Assay using the Ion S5 XL System. The study of genetic information from cell-free DNA (cfDNA) may impact future oncology diagnosis and treatment. READ 2017 January Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Inflammatory breast cancer is a highly aggressive form of locally advanced breast cancer representing up to 5% of breast cancers. READ 2017 February Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Curative therapies are most successful when cancer is diagnosed and treated at an early stage. READ 2017 May Leveraging natural killer cells for cancer immunotherapy. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. READ 2017 November Evolution of genetic instability in heterogeneous tumors. Genetic instability is an important characteristic of cancer. READ 2018 May Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. READ 2018 November Application of Cell-free DNA Analysis to Cancer Treatment. Tumor biopsies represent the standard for cancer diagnosis and the primary method for molecular testing to guide the selection of precision therapies. READ 2018 November Co-transplantation of mesenchymal stem cells improves spermatogonial stem cell transplantation efficiency in mice. Spermatogonial stem cell transplantation (SSCT) could become a fertility restoration tool for childhood cancer survivors. READ 2019 January The spleen may be an important target of stem cell therapy for stroke. Stroke is the most common cerebrovascular disease, the second leading cause of death behind heart disease and is a major cause of long-term disability worldwide. READ本页其他语言版本: English Italiano
